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Abstract
Objectives. To identify whether sleep disturbances are more prevalent in primary SS (pSS) patients
compared with the general population and to recognize which specific sleep symptoms are particularly
problematic in this population.
Methods. Electronic searches of the literature were conducted in PubMed, Medline (Ovid), Embase (Ovid),
PsychINFO (Ovid) and Web of Science and the search strategy registered a priori. Titles and abstracts
were reviewed by two authors independently against a set of prespecified inclusion/exclusion criteria,
reference lists were examined and a narrative synthesis of the included articles was conducted.
Results. Eight whole-text papers containing nine separate studies met the inclusion criteria and were
included in the narrative analysis. Few of these studies met all of the quality assessment criteria. The
studies used a range of self-reported measures and objective measures, including polysomnography.
Mixed evidence was obtained for some of the individual sleep outcomes, but overall compared with
controls, pSS patients reported greater subjective sleep disturbances and daytime somnolence and
demonstrated more night awakenings and pre-existing obstructive sleep apnoea.
Conclusions. A range of sleep disturbances are commonly reported in pSS patients. Further polysomno-
graphy studies are recommended to confirm the increased prevalence of night awakenings and obstruct-
ive sleep apnoea in this patient group. pSS patients with excessive daytime somnolence should be
screened for co-morbid sleep disorders and treated appropriately. Interventions targeted at sleep difficul-
ties in pSS, such as cognitive behavioural therapy for insomnia and nocturnal humidification devices, have
the potential to improve quality of life in this patient group and warrant further investigation.
Key words: Sjo¨gren’s syndrome, systematic review, sleep, quality of life, disability evaluation
Rheumatology key messages
. Sleep disturbances are common in primary SS patients and should be identified and treated appropriately.
. Interventions targeted at sleep difficulties in primary SS warrant further investigation.
Introduction
Primary SS (pSS) is a systemic autoimmune disease
characterized by sicca symptoms [1]. Extraglandular
features are commonly seen in pSS patients, including
fatigue [2], orthostatic intolerance [3], pain [4] and depres-
sion [5]. These patients commonly experience impaired
function [6] and poor health-related quality of life [8].
Fatigue is seen in 75% of patients with pSS [7], is strongly
correlated with poor quality of life [810] and is associated
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with functional impairment [6]. Due to the prevalence and
impact of fatigue, there has been much research into fac-
tors associated with this symptom, including potential
genetic associations [11] and anti-inflammatory mechan-
isms [12]. Sleep disturbances have also been reported in
the pSS literature [13] and are associated with fatigue [2].
In the general population, impaired sleep is associated
with adverse health outcomes including weight gain, de-
pression, pain, impaired immune function, impaired func-
tional performance, increased risk of early mortality and
cognitive symptoms such as increased errors and
increased risk of accidents [14]. Current recommenda-
tions are that adults should regularly have between 7
and 9 h of sleep consistently per night [14].
Many sleep disturbances are potentially modifiable
[1518]. Therefore the successful identification and treat-
ment of sleep problems may have a positive effect on
symptoms such as pain, mood and fatigue, resulting in
improvements in physical and cognitive functioning and
quality of life.
A previous review of sleep disturbances in rheumato-
logical diseases included pSS [19], but this review was
published some time ago and the pSS section was pre-
dominantly based on one comparative study that used
Rheumatoid arthritis (RA) patients as controls. Thus an
up-to-date systematic review of the pSS sleep literature,
including normative data on healthy controls, is required.
The aim of this review was to identify all the published
literature on sleep difficulties in pSS in order to answer the
following questions: Are sleep difficulties more prevalent
in pSS patients than in the general population and which
sleep difficulties are more prevalent in pSS patients than
in the general population?
Methods
A systematic review of the published literature on sleep
and pSS was conducted. The protocol was published pro-
spectively with PROSPERO, an international prospective
register of systematic reviews (CRD42015024977) [20].
The methodological framework used was the Preferred
Reporting Items for Systematic Reviews and Meta-ana-
lyses statement [21].
Eligibility criteria
Eligible studies were English-language primary research
papers published in full. These included intervention, diag-
nostic, prognostic and aetiological studies with adult par-
ticipants (>18 years) with a diagnosis of pSS. Case
studies and review papers were excluded. Where
papers report mixed populations, only studies that ana-
lysed the pSS population separately were included.
Outcomes had to include sleep outcomes and other out-
comes that have a relationship with sleep. In mixed popu-
lation studies, pSS data had to be reported separately for
pSS patients. Data for pSS had to be compared with a
control population, which could be healthy controls or
controls with other diseases. Therefore studies that did
not compare data from a pSS group with a non-pSS con-
trol group were excluded from this review.
Search strategy
Databases [PubMed, Medline (Ovid), Embase (Ovid),
PsychINFO (Ovid) and Web of Science] were searched
from inception to September 2015 using a prespecified
search string (supplementary Table 1, available at
Rheumatology Online). The references of all included stu-
dies were also searched. Two reviewers (K.H. and Z.G.)
independently examined the titles and abstracts of all re-
cords identified and full papers were retrieved for all
papers that met inclusion criteria. All full-text articles
were screened by two review authors independently
(K.H. and K.D.) for inclusion.
Data extraction and quality assessment
Data were extracted by one author (K.H.) onto a piloted
form. These were checked by a second author (K.D.). Risk
of bias was assessed at the study level separately by two
authors (K.H. and K.D.) using the Joanna Briggs Institute
Prevalence Critical Appraisal Tool [22] and specific notes
for questions within the tool were agreed upon between
the authors (K.H. and K.D.) to reduce ambiguity prior to
making a decision for each criteria (supplementary Table
2, available at Rheumatology Online). Disagreements be-
tween reviewers were resolved through discussion.
Summary measures
Any sleep summary measure that compared a pSS cohort
with a comparative group was extracted. These include
differences in means and medians and odds ratios. Data
were combined in a narrative synthesis due to the ex-
pected heterogeneity of the included studies.
Results
Nine studies from eight publications were identified for
inclusion in this narrative review [13, 2329] (Fig. 1). A
summary of the included studies are in Table 1. Sixteen
studies did not meet the inclusion criteria. Excluded stu-
dies with reasons for exclusion can be found in supple-
mentary Table 3, available at Rheumatology Online. One
excluded study was a small uncontrolled study (n= 9) of a
nocturnal humidification device that reduced nocturnal
sicca symptoms in the participants [30]. Another excluded
study included the use of an artificial saliva water spray,
compared with placebo, to improve nocturnal oral dry-
ness symptoms, as improvements were demonstrated in
both the placebo and intervention groups [31]. This review
did not set out to investigate interventions for pSS sleep
disturbances, but these findings are considered in the
context of potential future interventions in the discussion.
A total of 93 records were screened. Most studies were
excluded at the title stage, as they were not relevant to the
review or did not fit the inclusion criteria (Fig. 1). Fourteen
publications were examined in more detail before
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exclusion (supplementary Table S1, available at
Rheumatology Online) and nine studies from eight publi-
cations were included in this narrative review [13, 2329]
(Table 1). Gudbjo¨rnsson et al. [23] included two studies in
their paper and these are referred to as Gudbjo¨rnsson et
al. study 1 (a comparative study of sleep symptoms in
three populations) and study 2 (a polysomnography
study) in this review for clarity.
Assessment of bias
The risk of bias quality assessment findings of the
included studies are presented in Table 2. Three studies
included only female pSS participants [13, 24, 29] and
were consequently deemed as not being representative
of the target population. Two studies (Gudbjo¨rnsson et
al. studies 1 and 2) [23] used the Copenhagen
Classification Criteria [32] to identify their subjects.
These criteria are not validated or accepted universally
[40], therefore these studies were also scored as not
being representative of the target population. The remain-
ing studies [13, 2429] used either the European
Community criteria [41] or the American European
Consensus Group criteria [40].
Several studies did not fully specify how their partici-
pants were recruited (including Gudbjo¨rnsson et al.
studies 1 and 2) [13, 23, 24, 28] and uncertainty re-
mained for this item for these studies. The sample size
was small (<40) for a number of studies (including
Gudbjo¨rnsson et al. study 2) [13, 23, 24, 27, 28] and
these studies were scored as being at high risk of bias
for this question.
Overall, three studies were deemed to be of high risk
of bias (including Gudbjo¨rnsson et al. study 2) [13, 23, 24],
four at medium risk of bias (including Gudbjo¨rnsson et al.
study 1) [23, 2729] and two at low risk of bias [25, 26].
Prevalence of specific sleep difficulties
in pSS
The main sleep outcomes are shown in Table 3. Perceived
sleep disturbance (measured by sleep diary or patient-re-
ported sleep questionnaires) was reported in four studies
(including Gudbjo¨rnsson et al. study 1) [13, 23, 26, 28].
Odds ratios (ORs) were calculated from the data provided
by one study [26]. pSS patients scored significantly worse
than healthy controls for this outcome. It was unclear
whether overall there is a higher prevalence of sleep dis-
turbance in pSS patients compared with other disease
groups (OA, RA, SLE), as there were inconsistent findings
between the studies.
Time spent in bed was assessed in two studies with
conflicting findings. One study objectively assessed this
outcome with polysomnography (Gudbjo¨rnsson et al.
study 2 [23]) and the other measured time in bed subject-
ively with a patient-reported sleep questionnaire [25].
However, the study that reported no difference for this
outcome between pSS patients and healthy controls
FIG. 1 Flow diagram of articles included in this review
Records idenﬁed through database 
searching 
(n = 92) 
Addional records idenﬁed through 
references of included papers 
(n = 1) 
Records screened 
(n = 93) 
Records not meeng the 
selecon criteria 
(n = 69) 
Full-text arcles assessed for 
eligibility 
(n = 24)
Full-text arcles not meeng the 
selecon criteria 
(n = 16) 
Papers included in the narrave 
synthesis 
(n = 8) 
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(Gudbjo¨rnsson et al. study 2) [23] had very small numbers
and took the measurements in a laboratory. The polysom-
nography study protocol and environment may have influ-
enced how long a participant remained in bed. Therefore it
is unclear whether pSS patients spend a longer time in
bed compared with other populations.
We identified five separate studies that examined total
sleep duration, including the Gudbjo¨rnsson et al. studies 1
TABLE 1 Summary of included studies
Author, year and country Study design Participants Sleep outcomes
Goodchild et al., 2010, UK
[13]
Observational prospective
study
pSS: n = 14, AECG diagnostic criteria for
pSS [29], 100% female, mean age 58
years, MDD 13 years
Sleep diary
RA: Rheumatoid arthritis n = 25, 100%
female, mean age 62 years, MDD 9
years
Actigraphy
Gudbjo¨rnsson et al., 1993,
Sweden [23]
Study 1: cross-sectional sleep
questionnaireStudy 2: ob-
servational study
Polysomnography for two
consecutive nights
Study 1: Study 1: Uppsala Sleep
Inventory [34]
pSS: n = 40, Copenhagen diagnostic cri-
teria for pSS [32], 95% female, mean
age 53 years. Ten pSS patients also had
PSG
Study 2: polysomnography
RA: n = 42, ARA criteria for classical RA:
Rheumatoid arthritis [33], 100%
female, 10 had symptoms of second-
ary SS
HC: n = 60, 100% female, age matched
with the pSS participants
Study 2:
pSS: n = 10, no demographic informa-
tion provided
HC: n = 30, middle-aged
Hilditch et al., 2008, Australia
[24]
Observational study over a
night’s sleep
pSS: n = 11, AECG diagnostic criteria for
pSS, 100% female, mean age 61 years,
MDD not reported
Electroencephalogram,
electrooculogram, sub-
mental electromyogram;
respiratory (inspiratory
flow, end-tidal CO2 and
mask leak); breathing
effort; upper airway col-
lapsibility; oral wetness
and saliva surface tension
HC: n = 8, all female, mean age 55.9
years, age matched with patient group
Theander et al., 2010,
Sweden [25]
Cross-sectional survey pSS: n = 77, AECG criteria for pSS, 90%
female, median age 61 years, MDD 12
years
Epworth Sleepiness Scale
[35], Restless Legs
Syndrome Questionnaire
[36], Lund University Sleep
Questionnaire [25], Profile
of Fatigue, fatigue VAS
HC: n = 59, 90% female, median age 55
years
Tishler et al., 1997, Israel [26] Cross-sectional survey pSS: n = 65, AECG classification criteria
for pSS, 92% female, mean age 57.3
years, MDD 8.3 years
Mini Sleep Questionnaire
[26]
RA (group A): n = 67, 83% female, MDD
12.6 years
RA with sicca symptoms (group B): n =
63, 70% female, MDD 15.1 years
OA: n = 31, 94% female, MDD 10.3
years
Usmani et al., 2012, Australia
[27]
Observational study pSS: n = 28, 100% female, AECG classi-
fication criteria for pSS, mean age 58.7
years, MDD not stated
Epworth Sleepiness Scale,
polysomnography,
Apnoea-Hypopnea Index
[27]HC: n = 18, 100% female, mean age
55.8 years
van Oers et al., 2010,
Netherlands [28]
Repeated measures study to
compare variability of fa-
tigue during the day
pSS: n = 29, 100% female, AECG criteria
for pSS, mean age 53.3 years, MDD not
stated
15-item Dutch questionnaire
on sleep quality [37]
SLE: n = 23, 100% female
RA: n = 19, 100% female
HC: n = 52, 100% female, mean age 51
years
Walker et al., 2003, Australia
[29]
Compared differences in urin-
ary symptoms and daytime
sleepiness
pSS: n = 76, European Community criteria
for pSS, 100% female, median age 58
years, MDD not stated
Epworth Sleepiness Scale,
FACIT-F [38], American
Urological Symptom Index
[39]OA: n = 43, 100% female, median age
64 years
AECG: American-European Consensus Group Criteria; ARA: American Rheumatism Association; HC: healthy controls; MDD:
mean disease duration; OSA: obstructive sleep apnoea; VAS: visual analogue scale.
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and 2 [13, 23, 24, 27]. Three small studies [13, 24, 27]
compared a total of 53 pSS patients with RA patients
(n= 25) [13] or healthy controls (n= 26) [24, 27]. They
found no significant differences between the groups in
terms of total sleep time. However, Gudbjo¨rnsson et al.
study 1 [23] compared 40 people with pSS with 42 people
with RA and 60 healthy controls. They found that people
with pSS reported significantly less sleep than the com-
parators as measured by sleep diaries (40 min1 h 45 min
less), while in their smaller polysomnography study (study
2) they found that pSS patients experienced 1 h
18 min2 h less sleep than healthy controls.
Three studies examined the proportions of time spent in
each of the stages of sleep between pSS patients and
controls (including Gudbjo¨rnsson et al. study 2) [23, 24,
27]. Two found that pSS patients spent more time in stage
1 sleep than controls (Gudbjo¨rnsson et al. study 2) [23,
24]. However, Usmani et al. [27] found no such difference.
None of the studies found between-group differences for
other stages of sleep.
Sleep onset latency (time taken to fall asleep) was not
significantly different between pSS patients, RA patients
and healthy controls using self-reported methods in one
study (Gudbjo¨rnsson et al. study 1) [23], although the au-
thors did not make a direct comparison between the pSS
and control groups. However, two studies (including
Gudbjo¨rnsson et al. study 2) [23, 27] involving objective
testing of this outcome (polysomnography) did find sleep
onset latency to be greater in pSS patients (mean
2022 min) compared with controls (mean 13.8 [27],
range 1.513.6 min [23]).
Sleep efficiency (percentage of time spent in bed
asleep) was identified as reduced in people with pSS in
two studies (including Gudbjo¨rnsson et al. study 2) [13,
23], both of which used objective measures. In a third
study [24] with very low numbers, the sleep efficiency
was very poor for both groups. However, this could be
due to the nasal mask that participants wore and the regu-
lar negative pressure pulses used to measure airway col-
lapsibility, which may have interfered with their sleep.
Thus the environment was not ideal to examine sleep ef-
ficiency in this study.
All studies that examined the number of night awaken-
ings found that these were increased in pSS patients
(Gudbjo¨rnsson et al. study 2 and Theander et al.) [23,
25] (see Table 3). That being said, the polysomnography
studies that report an arousal index (number of times
sleep is interrupted) found no difference between pSS pa-
tients and comparison groups [24, 27].
Factors associated with disturbed sleep
A number of studies examined specific reasons for waking
in the night. Theander et al. [25] noted that 13% of their
pSS group reported sicca symptoms that disturbed their
sleep, compared with none of their controls.
Hilditch et al. [24] found that nocturnal oral dryness did
not differ significantly between pSS patients and controls,
which is surprising, but due to their very low numbers,
could be a type II error. The same authors found that
saliva surface tension showed no difference between the
groups in the early morning but was significantly higher in
the pSS group in the late evening.
Nocturnal pain and disturbed sleep was more common
in pSS compared with controls and RA patients
(Gudbjo¨rnsson et al. study 1 and Theander et al.) [23,
25]. Gudbjo¨rnsson et al study 1 [23] reported that 54%
of their pSS group experienced nocturnal pain compared
with 37% of their RA group (P< 0.01) and 0% of their
healthy control group (P< 0.0001). Theander et al. [25]
found that nocturnal pain that disturbed sleep was present
in 19% of their pSS group, which was >9% of those in the
control group, although this difference was not significant
(P= 0.07).
There was conflicting evidence from two studies for
nocturia disturbing sleep in pSS patients. Walker et al.
[29] investigated nocturia and found no difference be-
tween pSS patients and an OA population for the occur-
rence of this symptom (OR 0.93, P= 0.85). Conversely,
Theander et al. [25] found that 53% of their pSS partici-
pants experienced nocturia that disturbed sleep
compared with 26% of their healthy controls (P= 0.001).
Autonomic symptoms
Nocturnal autonomic symptoms were only investigated by
Gudbjo¨rnsson et al. study 1 [23], which found 20% of the
pSS participants in this study reported experiencing noc-
turnal sweating, which was greater than their RA compari-
son group (12%, NS) and their healthy controls (2%,
P< 0.01). Palpitations at night were reported in 5% of
their pSS group, which were not present in either their
RA or healthy control groups.
Presence of co-morbid sleep disorders
In Theander et al.’s study [25], 2 of their 72 patient pSS
cohort self-reported a diagnosis of narcolepsy, compared
with none of their controls, but this was not reported as an
outcome in any of the other included studies.
Using polysomnography, one study noted the occur-
rence of obstructive apnoeas and hypopnoeas were
double in their pSS group compared with healthy controls
[27]. In this study, continuous positive airway pressure
(CPAP) treatment was offered to 8 of 28 pSS study par-
ticipants who were identified as having severe sleep
apnoea (with an apnoea-hypnoea index score 540).
Five participants accepted the treatment and significant
improvements were demonstrated both in their Epworth
Sleepiness Scale (ESS) scores and fatigue scores at 26
months after commencing CPAP treatment.
However, another study [24] investigated upper airway
collapsibility and found no difference in both the upper
airway collapsibility index and a range of respiratory vari-
ables between their pSS and control groups, but this
could be due to the study being underpowered.
Daytime somnolence
Four studies identified increased daytime sleepiness in
patients with pSS compared with healthy controls.
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Gudbjo¨rnsson et al. study 1 [23] found their pSS patients
were sleepy in the daytime five times more frequently than
RA controls and almost three times more frequently than
healthy controls. Theander et al. [25], Usmani et al. [27]
and Walker et al. [29] reported that ESS scores were sig-
nificantly higher in pSS patients than in controls.
Discussion
Findings of the review
We have found that subjective and objective sleep dis-
turbances are more common in pSS patients. Further re-
search is needed to examine the differences between pSS
patients and other disease groups.
There were inconclusive findings regarding whether
pSS patients spend more time in bed than comparative
groups, however, if they do spend longer in bed, it is likely
that this is due to the sleep disturbances and night awa-
kenings they experience. Because of the conflicting find-
ings in this review, further studies are needed to confirm
whether pSS patients have a short sleep duration com-
pared with other groups. However, pSS patients do seem
to experience more frequent nocturnal awakenings than
other groups. Despite this finding, the arousal index
scores were not found to be greater for pSS patients in
the studies that examined this outcome. One reason could
be due to low numbers of participants in these studies.
However, an alternative suggestion is that the pSS pa-
tients awaken more frequently during these arousals due
to their symptoms, such as dryness, pain and autonomic
symptoms. A further possibility is that pSS patients may
demonstrate high-frequency electroencephalographic ac-
tivity throughout the night that may influence their percep-
tion of sleep and wakefulness. Further investigations are
required to test this.
Sicca symptoms did disturb sleep in one study [25] and
potential interventions to reduce these symptoms and
thus improve sleep will be discussed shortly. Pain is an-
other symptom that is more common in pSS patients
during the night. Segal et al. [4] observed that sleep quality
is reduced as pain increases. Thus if pain is reduced,
sleep quality may improve.
There were conflicting findings regarding the symptom
of nocturia in pSS patients. Since pSS patients regularly
drink to ease the symptoms of their dryness, needing the
toilet during the night could be a natural consequence of
this.
Although autonomic symptoms were only reported in
one included study, there is a greater prevalence of
these symptoms in pSS patients [3] and it is logical that
these symptoms, which can include palpitations, dizzi-
ness and sweats, may interfere with sleep.
There does seem to be an increased prevalence of ob-
structive sleep apnoea in pSS patients, although further
studies are needed to reproduce this finding. The ESS can
be used as a screening tool to identify patients who are at
risk of obstructive sleep apnoea [42] and these patients
should be referred for further investigations.
This review has demonstrated that daytime sleepiness
is a problem in pSS patients. Daytime sleepiness correl-
ates with reduced quality of life [10], fatigue [25, 29], auto-
nomic dysfunction [3] and functional impairment [6].
Furthermore, patients who are functionally impaired have
significantly greater ESS scores than those who experi-
ence no functional disability [6].
Potential interventions for sleep disturbances in pSS
Interventions that address the perception of poor sleep
without the necessity for objective verification include ad-
dressing unhelpful beliefs surrounding sleep, addressing
sleep efficiency and prescribing time in bed. These are all
components of a Cognitive Behavioural Therapy for
Insomnia (CBT-I) intervention [43]. CBT-I is considered a
first-line treatment for insomnia associated with a medical
condition [44] and is an effective intervention in other long-
term conditions [45], therefore it could be beneficial in
pSS. Time in bed and sleep efficiency are both addressed
in the sleep restriction component of a CBT-I intervention
and this may be a useful way of addressing longer time
spent in bed awake in this patient group and lead to im-
proved sleep. Further studies of CBT-I and various modes
of delivering this intervention are therefore warranted in
this patient group.
Nocturnal humidification and artificial saliva sprays may
ease nocturnal sicca symptoms and decrease sleep dis-
turbances in pSS patients and are unlikely to contribute
to bladder disturbances during the night. Although a hu-
midification device did seem to be a promising interven-
tion in an excluded study [30], further appropriately
powered studies comparing nocturnal humidification de-
vices in pSS with controls are required to demonstrate
efficacy.
For autonomic symptoms that interfere with sleep, ap-
propriate interventions addressing these symptoms, such
as water bolus treatment during the day [46], may also
help to improve sleep, particularly if these symptoms are
regularly experienced during the night. Further research is
required to demonstrate the efficacy of interventions for
dysautonomia in pSS, such as blood pressure dysregula-
tion, on sleep outcomes.
Further considerations
A more detailed sleep assessment, including polysomno-
graphy, may be beneficial for this group when considering
the level of sleep apnoea reported in this population.
Moreover, polysomnography will afford a closer examin-
ation of other objectively verifiable sleep disorders
that may influence sleep (e.g. narcolepsy, periodic limb
movement disorder, restless legs syndrome and hyper-
somnolence disorders). If severe sleep apnoea is identi-
fied in pSS patients, CPAP treatment should be offered
[47].
Pain is another symptom that can interrupt sleep. pSS
patients who experience pain that is interfering with their
sleep should be offered appropriate pain management
interventions [4]. CBT-I is efficacious in improving sleep
duration, continuity and perceived quality in chronic pain
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patients with co-morbid insomnia and CBT-I with an add-
itional pain component is feasible [45]. A pain adjunct to a
CBT-I intervention may therefore improve sleep in pSS
patients with chronic pain. Interventions targeting sleep
disturbances in pSS may improve daytime sleepiness
and fatigue, which could result in increased functional
capacity and quality of life.
There are some limitations to this review. First, although
we did not specifically investigate potential causes of
sleep disturbances, we uncovered several potential con-
tributing factors from within the included studies.
However, there may be further potential complications in
pSS that might play a role in sleep disturbance, such as
gastro-oesophageal reflux [48]. Further work needs to be
done to determine the causes of sleep disturbances in this
patient group. Second, although we did not set out to
investigate specific interventions for sleep disturbances,
we identified some uncontrolled studies of interventions
for sleep in pSS. There may therefore be further studies of
interventions for sleep disturbances in pSS uncovered by
our search. However, a recent systematic review of all
non-pharmacological interventions for pSS did not identify
any randomized controlled trials for sleep difficulties in this
patient group [49]. Furthermore, recent meta-analysis of
23 studies determined that CBT-I was efficacious in redu-
cing sleep disturbances and improving sleep quality in
patients with insomnia secondary to a co-morbid condi-
tion [50].
This review included a total of 350 pSS patients in nine
separate studies. Only two studies (with 142 pSS patients)
were deemed to be at low risk of bias. This highlights the
paucity of high-quality research into sleep disturbances in
pSS patients.
Conclusion
From the included studies in this review, we found an
increased prevalence of sleep disturbances in pSS pa-
tients compared with controls, including daytime somno-
lence, subjective sleep disturbances (including
disturbance due to dryness symptoms) and increased oc-
currence of night awakenings. Sleep apnoea may be more
common, but further polysomnography studies are
required to confirm this.
Although we did not set out to investigate interventions,
logic dictates that CBT-I for sleep disturbances and night
awakenings and nocturnal humidifiers for nocturnal sicca
symptoms would be beneficial in this patient group.
However, further studies are required to confirm their ef-
fectiveness in pSS. Due to the variable quality of the
included studies, the mix of outcomes assessed within
these studies and the overall low numbers of patients
included within them, we recommend further studies to
add to the body of pSS sleep prevalence literature.
Finally, in the presence of sleep difficulties in pSS pa-
tients, primary sleep disorders should be screened for
and treated appropriately.
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